Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Radaszkiewicz

Showing results (151-160 of 154) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 154 results.
Annals of Hematology|December 24, 1997
Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor TherapyM A Fridrik, R Greil, H Hausmaninger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996
CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trialM A Fridrik, H Hausmaninger, W Linkesch, et al.
Annals of Hematology|October 1, 1996
Spontaneous remission of acute myeloid leukemia after infection and blood transfusion associated with hypergammaglobulinaemiaM Mitterbauer, M Fritzer-Szekeres, G Mitterbauer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 15, 1995
Differential expression of complement receptors on human basophils and mast cells. Evidence for mast cell heterogeneity and CD88/C5aR expression on skin mast cellsW Füreder, H Agis, M Willheim, et al.
Pageof 16

Showing results (151-160 of 154) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 154 results.
Annals of Hematology|December 24, 1997
Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor TherapyM A Fridrik, R Greil, H Hausmaninger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996
CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trialM A Fridrik, H Hausmaninger, W Linkesch, et al.
Annals of Hematology|October 1, 1996
Spontaneous remission of acute myeloid leukemia after infection and blood transfusion associated with hypergammaglobulinaemiaM Mitterbauer, M Fritzer-Szekeres, G Mitterbauer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 15, 1995
Differential expression of complement receptors on human basophils and mast cells. Evidence for mast cell heterogeneity and CD88/C5aR expression on skin mast cellsW Füreder, H Agis, M Willheim, et al.
Pageof 16